title: [Role of alfuzosin in the treatment of functional voiding disorders in women].
abstract: Voiding dysfunction of the lower urinary tract represent a diagnostic and therapeutic challenge being the symptoms and urodynamic finding not strictly related. 34 women with urgency-frequency symptoms and post voiding residual urine were treated with alfuzosin 2.5 mg. twice daily alone or associated to oxibutinine 25 mg twice daily in patients with destrusor instability. After 30 days from therapy 69% presented a post void residual urine less than 40 ml, while 76% presented a flw max more than 15 ml/sec. At follow up 12 months the results remained unchanged. Alfuzosin alone or in association with oxibutinin can lower the urinary resistance to flow without modifying the maximum urethral pressure (MUP).
authors.affiliation: Clinica Urologica, Università Federico II di Napoli.
authors.forename: M
authors.initials: M
authors.lastname: D'Armiento
authors.forename: R
authors.initials: R
authors.lastname: Damiano
authors.forename: M
authors.initials: M
authors.lastname: De Sio
authors.forename: S
authors.initials: S
authors.lastname: Perdonà
authors.forename: C
authors.initials: C
authors.lastname: Santonastaso
authors.forename: D
authors.initials: D
authors.lastname: Mattace Raso
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*; D014555:Urination Disorders / Q000188:drug therapy*
chemical_list: D011799:Quinazolines; C047638:alfuzosin